Jump to content

pacestick

Member
  • Posts

    341
  • Joined

  • Last visited

pacestick's Achievements

Newbie

Newbie (1/14)

0

Reputation

  1. Its hard to start a vaccination programme without vaccine by that I mean it had to be developed and priority was always going to go to those wealthy countries with high infection/death rates However I agree with the rest of your post
  2. well the kiwis are enjoying it anyway . Barnaby Joyce is the the number two nominated person to be new zealander of the year 2018
  3. Expect a move to taxation by distance travelled so much a kilometre
  4. sorry should have posted second half 2017
  5. Goldman sachs presentation New York http://www.beachenergy.com.au/irm/PDF/6513...InvestmentForum Note the excess gas destined for the spot market second half 2016
  6. Based on the increase POO I am expecting a small increase in the dividend compared to the last half .
  7. adr comparison web site http://stockpar.com/index.php?id=2
  8. pacestick

    UNS

    I have no idea . They have dealt with the immediate short term financial crisis . There will be more contracts to come both from AMGEN and others over the next twelve months as the company edges towards profitability
  9. pacestick

    UNS

    Unilife and Amgen Enter Strategic Collaboration for Injectable Drug Delivery Systems Amgen to invest up to $75 million in leading technology platform Collaboration includes license agreement and master development and supply agreement YORK, Pa., Feb. 22, 2016 /PRNewswire/ -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS) today announced a strategic collaboration with Amgen (NASDAQ: AMGN), a leading biotechnology company, for injectable drug delivery systems. The collaboration, which includes licensing, investment, development and supply agreement components, is centered upon the use of Unilife's portfolio of prefilled, customizable wearable injectors for medicines to enhance the patient experience. Under the terms of the collaboration, Unilife has granted Amgen exclusive rights to Unilife's wearable injectors within select drug classes for use with certain Amgen assets, while preserving rights previously granted to other Unilife customers. Unilife has also granted Amgen non-exclusive rights to all proprietary Unilife delivery systems within the therapeutic areas of oncology, inflammation, bone health, nephrology, cardiovascular and neuroscience. "Unilife looks forward to a long-term strategic collaboration with Amgen to drive value for patients, prescribers and payers," said Ian Hanson, senior vice president and general manager of Unilife's Wearable Injector business unit. "Unilife is pleased to advance its leadership position in the wearable injectors market to meet growing demand for biologics and other medicines. Our prefilled, pre-assembled and ready-to-inject delivery systems are easy-to-use and enhance patient experience." "We are pleased to enter this collaboration with Unilife," said Alison Moore, senior vice president of Process Development at Amgen. "One important pillar of Amgen's strategy is to invest in leading drug delivery technologies to more effectively meet the needs of patients suffering from serious illnesses. Unilife continues to develop technology that could provide patients with innovative and meaningful enhancements to drug administration." Under the strategic collaboration, Unilife can receive up to $75 million. At closing, Amgen paid a nonrefundable $20 million license fee and purchased a $30 million senior secured convertible note from Unilife. Amgen may purchase up to an additional $25 million in senior secured convertible notes over the next two years ($15 million in January 2017 and $10 million in January 2018). These payments are in addition to Amgen's $15 million payment to Unilife in connection with the exclusivity letter entered into on December 31, 2015. In addition to these payments, Unilife expects to generate future revenue from the strategic collaboration with Amgen. The collaboration includes a master development and supply agreement that captures key terms for the development, production and supply of Unilife delivery systems. Development programs will commence in 2016. About Unilife Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S.-based developer and commercial supplier of injectable drug delivery systems. Unilife's portfolio of innovative, differentiated products includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, insulin delivery systems, ocular delivery systems and novel systems. Products within each platform are customizable to address specific customer, drug and patient requirements. Unilife's global headquarters and manufacturing facilities are located in York, Penn. For more information, visit www.unilife.com General: UNIS-G Investor Contacts (U.S.): Investor Contacts (Australia) Todd Fromer / Garth Russell Jeff Carter KCSA Strategic Communications Unilife Corporation P: + 1 212-682-6300 P: + 61 2 8346 6500 Forward-Looking Statements This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K, those described in the "Risk Factors" set forth in Unilife's prospectus supplement, dated as of and filed with the U.S. Securities and Exchange Commission on February 22, 2016, and those described from time to time in other reports which we file with the U.S. Securities and Exchange Commission. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/un...-300223649.html SOURCE Unilife Corporation
  10. <h2 class="hd">Search Results</h2> â–º 2:55<h3 class="r" style="font-size:18px"> </h3>youtube death star canteen 2 darth vader death star canteen-eddie izzard eddie izzard death star canteen download lego star wars cafeteria darth vader cafeteria jeff vader youtube to mp3 youtube funny
  11. pacestick

    UNS

    I would be surprised if AMGN -UNS deal is the only one going on the ASX at the moment, but I would be amazed if AMGEN UNIS deal is the only one going on with AMGN on the Nasdaq . AMGN is a very large company in a very healthy financial position with a very large number of activities occurring
  12. pacestick

    UNS

    why would they pay 15 million non refundable and walk away. A lways possible I suppose if not getting what they want but not I would think very likely. AS to it being over by the 31st as per the original release I would point out that the result of the Morgan Stanley negotiations was due by 31 December but there was no announcement before 4 January. So I will not be concerned if the announcement does not come before the end of next week.
  13. http://www.bloomberg.com/news/articles/201...il-to-the-world Before the most recent round of sanctions went into effect three years ago, Iran was able to sell oil to 21 countries. By mid-2012, that was down to six: China, India, Japan, South Korea, Taiwan, and Turkey. Rather than immediately pull back on production, and risk damaging oil wells by slowing them down, Iran decided to store its excess crude. As it scrambled to build onshore tanks, the government loaded millions of barrels onto its suddenly out-of-work fleet of crude-carrying vessels. The Iranians eventually reduced their oil output by about a third, to a low of 2.5 million barrels a day in mid-2013, according to data compiled by Bloomberg. As exports fell to 1 million to 1.5 million barrels a day, Iran kept filling its tankers with oil it couldn’t sell. By this summer, a large portion of its tanker fleet, one of the world’s biggest, sat parked off the coast, filled with 50 million to 60 million barrels of crude and condensate, a lighter form of oil used to make petrochemicals. http://assets.bwbx.io/images/i4v6..gVUF5g/v1/-1x-1.jpg Since the nuclear agreement between Iran and six other nations was reached on July 14, the regime has been preparing to ramp up its exports and sell that stored oil. A small number of Iranian tankers believed to have been storing crude has left the Persian Gulf in the past several weeks, according to data compiled by Bloomberg. Three of those ships have since disappeared from detection by failing to report their location. Iran’s crude output has been rising for two years and now stands at about 2.9 million barrels a day, the highest level since 2012. It won’t be allowed to sell that extra crude until sometime next year, when the International Atomic Energy Agency verifies that Iran has complied with curbs on its nuclear program. The monitoring needed for that to happen probably won’t be in place until January or February, say three Western diplomats familiar with the nuclear monitoring process. Oil Minister Bijan Namdar Zanganeh says sanctions will be lifted sooner. When they are, he says, production will rise immediately by a half-million barrels per day, and after four to five months, by an additional half-million barrels. He says that by then, “we will reach to a figure between 3.8 and 3.9 million barrels a day.†Saudi Arabia is pumping 10.5 million barrels daily. Even if Iran can increase production as quickly as Zanganeh claims, it may have to incentivize buyers by offering lower prices or by trading oil for goods or services, says Sara Vakhshouri, president of SVB Energy International, an energy consulting group in Washington. That’s because the Saudis have used long-term contracts to lock in customers who not long ago bought Iranian oil. The sanctions put in place in 2012 shrank the economy by about 10 percent by March 2014, according to the U.S. Congressional Research Service. A report by Anthony Cordesman of the Center for Strategic & International Studies in Washington estimates that Iran needs about $170 billion to develop its oil and gas potential. The decline in oil prices has led to a drop in Iran’s own investment in its oil and gas sectorâ€â€ÂÂÂÂfrom $40 billion in 2011 and 2012 combined to only $6 billion last year, Zanganeh says. The International Energy Agency estimates about half of Iranian production comes from oil fields that are more than 70 years old. Much of the money Iran has made through its remaining crude exports since 2012 is being held in escrow accounts in the various countries still buying Iranian crude. To reduce Iran’s access to cash, Congress passed a law requiring that Iran spend oil revenue only on goods from its customer countries. The Department of the Treasury estimates Iran will be able to retrieve half that amount, or about $56 billion. That’s still not enough to restart full oil production. And so the government is looking for foreign investment. Since July, political and business delegations from Austria, Germany, Italy, and Spain have visited Tehran. “I think European companies are very eager to be involved in our projects,†Zanganeh says. Iran has not met with U.S. companies, he says. “It seems they have received the order from the U.S. government not to have the meeting. The doors are open for them like others.†Some Iran watchers say Western companies will proceed with caution. “You’re not going to see an energy gold rush in terms of capital investment in Iran anytime soon,†says Mark Dubowitz, executive director of the Foundation for Defense of Democracies in Washington and a supporter of tougher sanctions. “The majors are still reluctant to make multibillion-dollar commitments to Iran.†â€â€ÂÂÂÂWith Jonathan Tirone, Julian Lee, and Grant Smith The bottom line: Iran says it will be pumping 3.9 million barrels a day by March, but its oil fields are old and need investment.
  14. pacestick

    UNS

    Unilife Announces Review of Strategic Alternatives Morgan Stanley Appointed as Strategic Advisor in Response to Expressions of Interest from Third Parties YORK, Pa., Sept. 2, 2015 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS and ASX: UNS), a developer, manufacturer and supplier of injectable drug delivery systems, today announced that in response to third-party initiated expressions of interest, the Company's Board of Directors has engaged Morgan Stanley & Co. LLC to conduct a review of strategic alternatives to maximize shareholder value. Potential strategic alternatives to be explored and evaluated during the review process may include a possible sale of the Company, a strategic partnership with one or more parties or the licensing of some of the Company's proprietary technologies. The Unilife Board of Directors will not provide any commitment regarding when or if this strategic review process will result in any type of transaction, and no assurance can be given that the Company will determine to pursue a potential sale, strategic partnership or licensing arrangement. Mr. Alan Shortall, Chairman and CEO of Unilife, said: "In keeping with the Board's commitment to act in the best interests of all shareholders, we have determined at this time that it is prudent to explore strategic alternatives to determine the best opportunities for enhancing shareholder value. Unilife management will continue to operate the business as normal during this review process to serve the needs of existing and prospective pharmaceutical customers." About Unilife Corporation Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's portfolio of innovative, differentiated products includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto injectors, wearable injectors, insulin patch pumps, ocular delivery systems and novel systems. Products within each platform are customizable to address specific customer, drug and patient requirements. Unilife's global headquarters and manufacturing facilities are located in York, PA. For more information, visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device. General: UNIS-G Forward-Looking Statements This press release contains forward-looking statements. All statements that address operating performance, or other events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/un...-300136764.html SOURCE Unilife Corporation
  15. p { margin-bottom: 0.25cm; line-height: 120%; } OK I made a mess of that so here it is typed Rig count overview and summary usa 21 august 2015 885 up 1 change from last year down 1011 canada 21 august 2015 208 down 3 change from last year down 197 international july 2015 down 28 change from last year down 264
×
×
  • Create New...